In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.
The in vitro activity of LY333328 was evaluated for 1,479 nosocomial gram-positive pathogens isolated in 12 countries during 1997. LY333328 MICs at which 90% of the isolates tested were inhibited for Enterococcus faecalis (n = 351), Enterococcus faecium (n = 100), Staphylococcus aureus (n = 593), coagulase-negative Staphylococcus species (n = 325), and Streptococcus pneumoniae (n = 110) were 1, 1, 2, 2, and 0.015 microg/ml, respectively. LY333328 demonstrated potent activity against isolates of vancomycin-resistant enterococci, oxacillin-resistant staphylococci, and penicillin-resistant pneumococci.
Zeckel
M L
ML
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
Preston
D A
DA
Allen
B S
BS
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology*; D006020:Glycopeptides; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance / Q000502:physiology; D020713:Vancomycin Resistance / Q000502:physiology; D014640:Vancomycin / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; C100708:oritavancin; D014640:Vancomycin